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Intestinal sickness is brought about by 
disease with a solitary cell parasite, 
Plasmodium. Four Plasmodium spp. cause 
jungle fever in people: Plasmodium 
falciparum, P. vivax, P. ovale, and P. malariae. 
P. falciparum is the most significant on the 
grounds that it represents most of 
contaminations and causes the most serious 
side effects. Jungle fever stays one of the main 
sources of horribleness and mortality in the 
tropics. As per the World Malaria Report 
(2019), there were in excess of 80 nations and 
territories with progressing intestinal sickness 
transmission in 2018. (1) 
Antimalarial drugs (2-6) 
Antimalarials are utilized in three unique 
manners: prophylaxis, treatment of falciparum 
jungle fever, and treatment of non-falciparum 
intestinal sickness. Prophylactic antimalarials 
are utilized only by voyagers from created 
nations who are visiting malaria endemic 
nations. Treatment conventions for falciparum 
jungle fever differ, contingent upon the 
seriousness of the malady; quick acting, 
parenteral medications are best for extreme, 
life threatening sickness. Various classes of 
Antimalarial Drugs act at various phases of 
intestinal sickness, fall into three general 
classifications as per their concoction structure 
and method of activity.  
The Classes are: 
Aryl aminoalcohol compounds (AAA) 
Aryl aminoalcohol compounds (AAA) 
meddling with heme dimerization, the 
detoxifying biochemical procedure inside the 
jungle fever parasite that typically yields 
intestinal sickness shade (hemozoin). Cross-
obstruction between antimalarials is identified 
with regular parts of their methods of activity 
just as their opposition systems. Parasites with 
elevated level chloroquine obstruction, are 
commonly impervious to amodiaquine too. 
The medications under this class incorporates 
quinine, quinidine, chloroquine, amodiaquine, 
mefloquine, halofantrine, lumefantrine, 
piperaquine, tafenoquine. 
Antifolate compounds (AFC) 
An antifolate compounds (AFC) like 
pyrimethamine, and biguanides, for example, 
cycloguanil meddle with folic corrosive union, 
hindering the parasite catalyst known as 
dihydrofolate reductase-thymidilate synthase 
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(DHFR). Sulfonamides act at the past advance 
in the folic corrosive pathway, restraining the 
parasite protein dihydropteroate synthase 
(DHPS). Ex. pyrimethamine, proguanil, 
chlorproguanil, trimethoprim. 
Artemisinin compounds (AMC) 
Artemisinin compounds (AMC) the 
artemisinins are powerful at slaughtering the 
broadest scope of agamic phases of the 
parasite, running from medium-sized rings to 
early schizonts; they likewise produce the most 
quick restorative reactions by quickening 
leeway of circling ring-stage parasites.The 
tranquilizes under this classification 
incorporates artemisinin, dihydroartemisinin, 
artemether and artesunate. 
Atovaquone compounds (AVC) 
Atovaquone is another mix sedate 
(comprising of atovaquone and proguanil) 
utilized for treatment and avoidance of 
chloroquine-safe P. falciparum. Atovaquone 
meddles with mitochondrial electron transport, 
and furthermore squares cell breath. Elevated 
levels of atovaquone obstruction result from 
single-point transformations in a quality 
encoding cytochrome b found on a little, 
extrachromosomal DNA-containing 
component in the parasite. 
Malaria is an ailment brought about by 
parasite of the class Plasmodium and it is 
transmitted through the chomps of tainted 
female mosquitoes of Anopheles species. In 
2018, there are around 223 million instances of 
jungle fever around the world. Most of cases 
(90%) are predominant in the African zone, 
South-East Asia and Eastern Mediterranean 
zones. this audit was intended to features and 
gives valuable data on different present and 
promising expository methodologies for 
technique improvement and approval, new 
advances, sought after by some imaginative 
focuses on that have been investigated till 
date.
[1]
 This survey additionally examines 
present day and cutting edge different logical 
ways to deal with antimalarial medicate like 
artemether and lumefantrine, strategy 
improvement with UV, HPLC, HPTLC, GC-
MS and LC-MS featuring the different 
strategies. 
Artemether (AME) (7,8) 
Artemether (AME ) is drug neutralizes the 
erythrocytic phases of Plasmodium falciparum 
by hindering nucleic corrosive and protein 
union. Artemether is a methyl ether 
subordinate of artemisinin, which is a 
peroxide-containing lactone confined from the 
antimalarial plant Artemisia annua. The 
chemical name of artemether is ((3R, 5aS, 6R, 
8aS, 9R, 10S, 12R, 12aR)- decahydro-10-
methoxy-3, 6, 9-trimethyl-3, 12-epoxy-
12Hpyrano [4,3-j]-1, 2-benzodioxepin). The 
atomic equation of AME C16H26O5 and sub-
atomic load of AME is 298.374 g/mol. 
Artemether is pale yellow solid with a 
dissolvability in natural solvents, for example, 
ethanol, DMSO (dimethyl sulfoxide) and DMF 
(dimethyl formamide).The partition 
coefficient( log p) for AME is 3.53 and PKA is 
3.9.
 
Lumefantrine (LFR) (9) 
Lumefantrine (LFR ) is a medication 
neutralizes the erythrocytic phases of P. 
falciparum by repressing the development of 
β-hematin by shaping a complex with hemin 
and hinders nucleic corrosive and protein 
blend. Lumefantrine and artemether blend 
treatment is demonstrated for the treatment of 
intense simple jungle fever brought about by 
Plasmodium falciparum, incorporating 
intestinal sickness gained in chloroquine-safe 
territories. 
 
Figure 1. Structural formula of Artemether 
The substance name of lumefantrine is (9Z)- 
2,7-dichloro-9-[(4-chlorophenyl) methylene]-
a-[(dibutyl amino) methyl]-9H-fluorene-4-
methanol. The empirical formula of LFR 
C30H32CL3NO and molecular weight of LFR is 
528.9 g/mol. 
It has the following structural formula, 
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Figure 2. Structural formula of Lumefantrine 
It is a white powder, dissolvable in DMF, 
chloroform, ethyl acetic acid derivation and 
dicloro-methane. The pKa is 8.73 and partition 
coefficient (log p) for LFR is 3.53. 
Artemether and Lumefantrine are presently 
accessible in fixed mix items, which are 
demonstrated to be exceptionally effectual for 
treatment of simple P. falciparum intestinal 
sickness. Artemether-lumefantrine (AME-
LFR) is the most well-known ACT utilized in 
jungle fever endemic territories. Artemether 
has a quick beginning of activity and is quickly 
dispensed with from the plasma (half-existence 
of a few hours. Lumefantrine is cleared all the 
more gradually and has a more drawn out end 
half-life (around 4.5 days). The method of 
reasoning behind this mix is that artemether at 
first gives fast indicative alleviation by 
decreasing the quantity of parasites present 
before lumefantrine dispenses with any 
remaining parasites. Artemether and 
lumefantrine likewise decreases gametocyte 
carriage and along these lines ought to have an 
impact on intestinal sickness transmission. The 
expanding utilization of these artemether 
lumefantrine blend against malarial items and 
the natural steadiness of these items require 
controlled capacity conditions. In this way, it is 
essential to have a quick, yet strong and 
soundness demonstrating quantitative strategy 
for the concurrent examine of artemether and 







Figure 3. HPLC Method of Analysis of Antimalarial Drugs 
2. HPLC Method of Analysis of 
Antimalarial Drugs 
High Performance Liquid Chromatography 
(HPLC) is a detachment procedure, it isolates 
blend containing at least two parts under high 
tension. In HPLC Stationary stage is stuffed in 
one finish of segment which is appended to a 
wellspring of pressurized fluid portable stage. 
HPLC is a quickest developing explanatory 
procedure for the investigation of the 
medication. Its effortlessness, high 
particularity and wide scope of affectability 
makes it perfect for the investigation of 
numerous medications in both measurements 
structure and natural liquids. A few hplc 
strategies were accounted for the investigation 
of antimalarial medicate in the mass, dose 
structure and natural liquids. (11-13)
 
A summary of research take a shot at a few 
expository techniques (HPLC, UV, HPTLC, 
UPLC and MS) announced for the artemether 
and lumefantrine alone and in blend is give in 
Table 1. 
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Table 1. A summary of research work on the 
analytical methods for the estimation of 
artemether and lumefantrine alone and in the 
combination. 
Sr. No. Drug Method Instrument, Mobile Phase, RT, Flow Rate & 
Results of Validation 




M.Phase :- 1N HCl 




Slope and intercept- 0.0182 and 0.006622 
 Detection Limit (μg/mL)- 2.30 




TLC   M.Phase :- Chloroform 




Slope and intercept- 2.108 and 0.856 
TLC – 100.7% 
UV- 97.7% 
3. Artemether (16)  HPTLC .   M.Phase :- Toluene: methanol: glacial acetic    
  acid (9: 1: 0.5, v/v/v)  
  λmax :- 235 nm, 
Result- 




 Detection Limit (ng/spot)- 2101.5 
Quatification limit (ng/spot)- 3697.74 
4. Artemether (17)  HPTLC .   M.Phase :- Toluene–ethyl acetate–formic acid   
  (8:2:0.3, v/v/v) 
  λmax :- 565 nm, 
Result- 




 Detection Limit (ng/spot)- 65.91 
Quatification limit (ng/spot)- 197.74 
5. β-Artemether 
liposomes (18) 
HPLC- UV   M.Phase :- Acetonitrile–water (75:25 v/v) (PH 
7.2) 
Flow Rate :- 1ml/min at 215 nm 
HPLC :- 




 LOD :- 2 μg/ml , LOQ:- 5 μg/ml 
6. Artemether (19) HPLC- UV in 
plasma and other 
body fluids. 
 M.Phase :- Acetonitrile- KH2PO4 buffer  (65:35 
v/v) (PH 6.5) 
Flow Rate :- 1ml/min at 210 nm 
HPLC :- 




 LOD :- 7.2 μg/ml , 
 LOQ:- 21.83 μg/ml 
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7. Artemether (20) RP-HPLC- PDA 
in plasma 
sample. 
 M.Phase :- Acetonitrile - water (70:30 v/v)  
Flow Rate :- 1.0 μL/min at 216 nm 
HPLC :- 




 LOD :- 0.5 μg/ml , LOQ:- 1.0 μg/ml 






  M.Phase :- acetonitrile – 0.05 M acetic acid 
(15:85, v/v) ( PH 5.0) 
Flow Rate :- 1.5 ml/min at 254 nm 
Result:- 
 R. Time :- 10.5 min.,  
 R
2-
0.9996 & 0.9998. 
   LOD :- 2.5 and 1.25 ng/ml 
   LOQ :- 2.5 and 1.25 ng/ml 






 M.Phase :- Acetonitrile – water (50:50 v/v) 
Flow Rate :- 0.7 ml/min at 254 nm 
Result:- 
 R. Time :- 10.5 min.,  
R
2-
0.992 & 0.991. 
 Intra & inter assay 8.0 and 14.2% for artemether 
& 8.0 
and 14.7% for dihydroartemisinin at 25 ng/ml. 






 M.Phase :- Methanol:10mM aqueous 
ammonium acetate (70:30 v/v)  
Flow Rate :- 500 μl/min 
Result:- 
 R. Time :- 1.3 & 2.83 min.,  
 LOD :- 0.36 ng/ml , LOQ:- 1.43 ng/ml 
11. Artemether and 
dihydroartemisinin 
(24) 
LC-MS/ MS in 
human plasma 
sample. 
 M.Phase :- MeCN- water  (85:15 v/v)  
 Flow Rate :- 10 μl/min 
Result:- 
 R. Time :- 4.9 & 2.5 min., 
 R
2-
0.998 & 0.999. 
 LOD :- 5 ng/ml & 2.5 ng/ml  
 LOQ:- 2 ng/ml 






 M.Phase :- Acetonitrile – water (80:20 v/v)  
Flow Rate :- 500 μl/min 
Result:- 
 R. Time :- 3.55 & 2.29 min., 
 R
2-
0.999 & 0.998. 
 LOD :- 0.3 ng/ml & 0.2 ng/ml  
 LOQ:- 0.8 ng/ml & 0.6 ng/ml  






 M.Phase :- Acetonitrile - 25 mM 
phosphatebuffer (75:25, v/v) 
Flow Rate :- 1.5 ml/min 
Result:- 
 R. Time :- 0.5 & 1.0 min., 
 R
2-
0.997 & 0.999. 
 LOQ:- 5.5 ng/ml & 11.48 ng/ml  
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  M.Phase :- Acetonitrile– glacial acetic acid 
0.1%  
   (66:34) 
Flow Rate :- 1.0 ml/min 
Result:- 
 R. Time :- 10.47 & 3.56 min., 
 R
2-
0.9965 & 0.9966. 
 LOQ:- 5.0 ng/ml.  






  M.Phase :- Acetonitrile– formic acid 0.1%  
   (80:20) 
Flow Rate :- 1.0 ml/min 
Result:- 
 R. Time :- 4.20 & 2.45 min., 
 R
2-
 0.995 & 0.9926 
 LOD:- 0.5 ng/ml & LOQ:- 5.0 ng/ml 






  M.Phase :- Methanol–ammonium acetate 
(10mmolL−1, pH 5.0, 80:20, v/v) 
Flow Rate :- 1.0 ml/min 
Result:- 
 R. Time :- 2 & 3.78 min., 
 R
2-
 0.9931 & 0.9925 
 LOQ:- 5.0 ng/ml &  6.0 ng/ml. 






  M.Phase :- Purified helium ( 99.999%) 
Flow Rate :- 0.9 ml/min 
Result:- 
 R. Time :- 10.3 & 9.78 min., 
 R
2-
  ˃0.988 
 LOD:- 100 pg/ ml. 
 LOQ:-  5.0 ng/ml. 




M.Phase :- 0.01 N NaOH solutions 




 Recovery:- 99.97%, 98.65%  & 98.91% 
LOD & LOQ:  
method I :- 0. 782, 1.465 μg/ml, 
method II :- 0.436, 1.214 μg/ml, 
method III :- 0.241, 0.362 μg/ml. 




M.Phase :- Methanol 
   λmax :-  234nm 




  Detection Limit - 4.3×10
-2
 
  Quantification limit - 13.2 ×10
-2
 
20. Lumefantrine (33)  UV-Vis Method 
& HPLC 
M.Phase :- Methanol 




 Detection Limit (μg/mL)- 0.1 
Quatification limit (μg/mL)- 0.3 
  HPLC 
  M.Phase :- Methanol - 0.05% trifluoroacetic 
acid          
   (80:20), flow rate ;-  1 ml/min. 
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 R. Time :- 5 
 Detection Limit (μg/mL)- 0.02 
 Quatification limit (μg/mL)- 0.05 
21. Lumefantrine (34) HPLC- UV in 
plasma 
 M.Phase :- Acetonitrile–phosphate buffer 0.1 M    
     (58:42 v/v) (PH 2.0) 
 Flow Rate :- 1.2 ml/min at 335 nm 
HPLC :- 
 R. Time :- 10.4 min 
 Recovery:- 85%,  
 LOD :- 10 ng/ml , LOQ:- 25 ng/ml 




 M.Phase :- Acetonitrile–phosphate buffer 0.1 M    
     (55:44 v/v) (PH 2.0) 
 Flow Rate :- 0.4 ml/min at 335 nm 
HPLC :- 




 Recovery:- 60-65%,  
 LOD :- 0.1 μM, LOQ:- 0.25μM 
23. lumefantrine and 
desbutyl 
lumefantrine (36) 
HPLC- UV in 
human plasma 
 M.Phase :- Acetonitrile - 0.05% trifluroacetic 
acid     
     (70:30 v/v) (PH 2.0) 
 Flow Rate :- 1.0 ml/min at 335 nm 
HPLC :- 
 R. Time :- 6 & 3.7 min 
 R
2- 
0.9998 & 0.9997 
 LOD :- 10 & 7.5 ng/ml 
 LOQ:- 18  & 15 ng/ml 
24. lumefantrine and 
desbutyl 
lumefantrine (37) 
HPLC- UV in 
human plasma 
 M.Phase :- Acetonitrile - phosphate buffer 0.1 M 
(55:45 v/v) (PH 2.0) 
 Flow Rate :- 1.2 ml/min at 335 nm 
HPLC :- 




 LOD :- 0.010 μg/mL 
 LOQ:- 0.024 & 0.021 μg/mL 
25. lumefantrine and 
desbutyl 
lumefantrine (38) 
HPLC- UV in 
whole blood 
spotted on filter 
paper 
   M.Phase :- Acetonitrile–ammonium acetate 
buffer 0.1M (10:90 v/v) (PH 6.5) 
 Flow Rate :- 1.0 ml/min at 335 nm 
 HPLC :- 
 R. Time :- 4.32 & 6.03 min 
 R
2- 
0.9989 & 0.9985 





HPLC- UV in 
tablet 
formulations 
   M.Phase :- Hexane - isopropanol (97:3)  
 Flow Rate :- 1.0 ml/min at 335 nm 
 HPLC :- 
 R. Time :- 6.54 & 6.67 min 
 R
2- 
0.9950 & 0.9948 
 LOD :- 3.9 & 4.3 μg/ml 
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 LOQ:- 11.5  & 13.2 μg/ml 
27. lumefantrine  (40)  HPTLC     M.Phase :- Methano l- water (9.5 + 0.5 v/v)   
   λmax :-   266 nm 
 HPLC :- 




 LOD :- 0.416 μg/ml 








 M.Phase :- Acetonitrile - ammonium acetate 
buffer 0.1 M  (90:10, v/v) (PH 4.9) 
Flow Rate :- 2 ml/min at 266 nm 
Result:- 




 LOD:- 0.004 mg/ml 
LOQ:-  0.026 mg/ml 
29. Lumefantrine (42) LC-MS/Ms in rat 
plasma. 
 M.Phase :- :- Acetonitrile - ammonium acetate 
buffer 0.01 M  (90:10, v/v) (PH 4.5) 
Flow Rate :- 0.5 ml/min 
Result:- 




 LOQ:- 2.0 ng/ml   
30. Lumefantrine (43) LC-MS/Ms in 
human plasma 
sample. 
 M.Phase :- Solvent A was aqueous ammonium 
formate 10 mM at pH 4.0. Solvent B was MeCN 
with FA 0.1%   
Flow Rate :- 0.4 ml/min 
Result:- 




 LOQ:- 50 ng/ml 




 M.Phase :- :- Acetonitrile - 0.1% formic acid 
(03:07, v/v)  
Flow Rate :- 0.5 ml/min 
Result:- 
 R. Time :- 1.37 min for WB samples & 1.12 min 




 LOQ:- 23.7 WB and 29.5 plasma 





 M.Phase :- 0.1% formic acid in water (solvent 
A) and acetonitrile (solvent B) 
Flow Rate :- 0.5 ml/min 
Result:- 




 LOQ:- 2.0 ng/ml 
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 M.Phase :- :- 0.5% formic acid in water (mobile 
phase A) and 0.5% formic acid in methanol 
(mobile phase B) 
Flow Rate :- 0.5 ml/min 
Result:- 




LOD:- 5.3 & 0.47 ng/mL 
 LOQ:- 19400 & 133 ng/mL 






M.Phase :- Ethanol 
   λmax :-  212 nm & 232nm 
Results :-  
R
2-
0.999 & 0.998,  
Recovery :- 100.31 for artemether & 99.78% for  
lumefantrine 
35. Artemether and 
Azithromycin (48) 
HPLC- UV   M.Phase :- Methanol - phosphate buffer 15mM     
 (80:20 v/v) (PH 9.0) 
 Flow Rate :- 1.0 ml/min at 210 nm 
HPLC :- 




 LOD :- 0.02 & 0.015 g/L 
 LOQ:- 0.3 & 0.4 g/L 
36. Artemether and 
Curcumin (49) 
HPLC- UV   M.Phase :- Acetonitrile- 0.1 % formic acid 
(60:40 v/v)  
 Flow Rate :- 0.7 ml/min at 216 nm 
HPLC :- 




 LOD :- 357.2 & 3.21 μg/mL 
 LOQ:- 1068.8 & 9.75 μg/mL 
37. Artemether and 
Lumefantrine (50) 
HPLC- DAD/UV   M.Phase :- Acetonitrile  
 Flow Rate :- 0.7 ml/min at 210 nm 
HPLC :- 




 LOQ:- 0.25 & 10 μg/mL 
Extraction recovery :- 96.2 % for artemether  & 
92.6 % for lumefantrine 
38. Artemether and 
Lumefantrine(51) 
HPLC- UV   M.Phase :- Acetonitrile- 0.05% trifluoroacetic 
acid  (60:40 v/v) (PH-2.35) 
 Flow Rate :- 1.0 ml/min at 210 nm 
HPLC :- 
 R. Time :- 2.9 & 3.89 min 
 R
2-  
 0.9984 & 0.9998 
 LOD :- 5 & 0.1 μg/mL 
 LOQ:- 15 & 0.5 μg/mL 
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39. Artemether and 
Lumefantrine (52) 
HPLC- UV   M.Phase :- Methanol - phosphate buffer  (50:50 
v/v) (PH-6.8) 
 Flow Rate :- 1.0 ml/min at 273 nm 
HPLC :- 
 R. Time :- 2.24 & 4.51 min 
 R
2-  
  0.9999 
 LOD :- 0.55 & 0.09 μg/mL 
 LOQ:- 1.35 & 0.32 μg/mL 
40. Artemether and 
Lumefantrine (53) 
HPLC- UV in 
human plasma 
 M.Phase :- Acetonitrile- methanol - 10 mM 
dipotassium orthophosphate  (42:38:20v/v/v) 
(PH-3.0) 
 Flow Rate :- 1.0 ml/min at 220 nm 
HPLC :- 
 R. Time :- 6 & 8.8 min 
 R
2-  
  0.9997 & 0.9994 
 LOD :- 1 & 0.04 μg/mL 
 LOQ:- 0.3 & 0.03 μg/mL 
41. Artemether and 
Lumefantrine (54) 
HPLC- PDA  M.Phase :- Methanol - 0.05% trifluoroacetic acid  
(80:20 v/v) (PH-2.8) 
 Flow Rate :- 1.5 ml/min at 210 nm 
HPLC :- 
 R. Time :- 6.15 & 11.31 min 
 R
2-  
  0.9999 
 LOD :- 0.0019 & 0.00047 μg/mL 
 LOQ:- 0.0060 & 0.0014 μg/mL 
42. Artemether and 
Lumefantrine (55) 
HPLC-UV  M.Phase :- Acetonitrile - 0.01M tetra butyl 
ammonium hydrogen sulphate  (80:20 v/v)  
 Flow Rate :- 1.0 ml/min at 222 nm 
HPLC :- 
 R. Time :- 4.19 & 5.22 min 
 R
2-  
  0.9999 
 LOD :- 0.201 & 2.99 μg/mL 
 LOQ:- 0.609 & 9.086 μg/mL 
43. Artemether and 
Lumefantrine (56) 
HPLC-UV  M.Phase :- Acetonitrile - 1mM phosphate buffer  
(52:48 v/v) (PH-3.0) 
 Flow Rate :- 1.5 ml/min at 210 & 335 nm 
HPLC :- 
 R. Time :- 3.07 & 1.70 min 
 R
2-  
  0.9997 
 LOD :- 3.4 & 0.1 μg/mL 
 LOQ:- 10 & 0.4 μg/mL 
44. Artemether and 
Lumefantrine (57) 
UPLC-UV  M.Phase :- Acetonitrile - 0.01N KH2PO4 (55:45 
v/v) (PH-3.5) 
 Flow Rate :- 0.3 ml/min at 215 nm 
HPLC :- 
 R. Time :- 0.787 & 1.572 min 
 R
2-  
  0.9992 & 0.9991 
 LOD :- 0.03 & 0.08 μg/mL 
 LOQ:- 0.03 & 0.08 μg/mL 
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45. Artemether and 
Lumefantrine (58) 
HPTLC    M.Phase :- N hexane–ethyl acetate (8:2 v/v)   
   λmax :-   357 nm 
 HPLC :- 




 LOD :- 0.5 ng/ml 
 LOQ:- 2 ng/ml 
46. Artemether and 
Lumefantrine (59) 
HPTLC    M.Phase :- Toluene:ethyl acetate:acetic acid 
(2:7.5:0.5, v/v/v)   
 λmax :-   269 nm & 519 nm 
 HPLC :- 
 Rf Value :- 0.55 & 0.70 
 R
2- 
0.9989 & 0.9999 
 LOD :- 2.43 & 7.32 ng per band 
 LOQ:- 6.12 & 26.15 ng per band 
47. Artemether and 
Lumefantrine (60) 
 HPLC- ESI- 
MS/MS 
 M.Phase :- Methanol - 10mMaqueous 
ammonium acetate containing 0.2% (v/v) acetic 
acid and 0.1% (v/v) formic acid. 
Flow Rate :- 1.0 ml/min  
HPLC :- 
 R. Time :- 4.2 & 6.7 min 
 R
2-  
  0.998 & 0.997 
 LOQ:- 10 ng/mL 
 
3. Conclusion  
Despite the fact that few diagnostic 
techniques (HPLC, UV, HPTLC, UPLC and 
MS) are accounted for there is a proceeded 
with requirement for growing progressively 
productive, sensitive, accurate and precise 
strategies for the examination of the artemether 
and lumefantrine alone and in mix in the dose 
structures and in the organic liquids. The blend 
of these medications is anything but difficult to 
manage and may improve adherence in the 
treatment of simple jungle fever brought about 
by plasmodium falciparum. 
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